DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cuprimine (Penicillamine) - Published Studies

 


Nutrilib.com
A comprihensive source of nutritional information

Cuprimine Related Published Studies

Well-designed clinical trials related to Cuprimine (Penicillamine)

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. [2004.02]

The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. [2001.03]

D-penicillamine is not an effective treatment in systemic sclerosis. [2001]

Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. [2000.11]

Penicillamine in the treatment of systemic sclerosis. [1999.10]

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. [1999.06]

Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine. [1998.10]

A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. [1998.09]

A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis. [1997]

D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. [1996.11]

Long term survival in Indian childhood cirrhosis treated with D-penicillamine. [1996.01]

Reversal of Indian childhood cirrhosis by D-penicillamine therapy. [1995.01]

Penicillamine in rheumatoid arthritis. A problem of toxicity. [1992.01]

Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study. [1992]

Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. [1991.06]

Toward a rational therapeutic strategy for arachnoiditis. A possible role for d-penicillamine. [1991.02]

A study of adjunctive copper sulphate treatment in patients with rheumatoid arthritis who have relapsed while taking D-penicillamine. [1991.01]

Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. [1990.04]

OM-8980 and D-penicillamine in the treatment of rheumatoid arthritis. A 12-month double-blind randomized study. [1990]

Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis. [1989]

Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E. [1988.11]

Prospective trial of penicillamine in primary sclerosing cholangitis. [1988.10]

Clinical trials of penicillamine in Indian childhood cirrhosis. [1987.11]

Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine. [1987.10]

Well-designed clinical trials possibly related to Cuprimine (Penicillamine)

Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20. [2004.05]

The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. [2004.04]

The development and evaluation of a drug information leaflet for patients with rheumatoid arthritis. [2003.01]

Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. [2001.09]

Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. [2000.06]

The Fifth Carlos E. Rubio Memorial Lecture. Sclerosing cholangitis: pathogenesis, pathology, and practice. [1999.03]

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. [1999.03]

Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. [1997.05]

Time course of histological progression in primary biliary cirrhosis. [1996.01]

[A prospective study of plasma exchange in the treatment of diffuse scleroderma] [1995.09]

Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis. [1994.12]

Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. [1993.08]

[A comparative controlled trial of 2 administration modalities of tiopronin in rheumatoid arthritis] [1993.05]

Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. [1992.03]

Cholangiocarcinoma complicating primary sclerosing cholangitis. [1991.01]

Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. [1990.08.04]

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. [1990.04]

Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. [1990.01]

Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis. [1988.01]

Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. [1985.11]

Other research related to Cuprimine (Penicillamine)

A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. [2008.05]

A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. [2008.02.16]

Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy. [2008.02]

Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. [2008.01.15]

Effect of penicillamine and zinc on iron metabolism in Wilson's disease. [2007.12]

D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. [2007.11]

Effect of oral D-penicillamine vs. colchicine on experimentally induced peritoneal adhesions in rats. [2007.10]

Effect of oral d-penicillamine vs. colchicine on experimentally induced peritoneal adhesions in rats. [2007.06.05]

D-Penicillamine administration and the incidence of retinopathy of prematurity. [2007.02]

Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease. [2007.02]

Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. [2007.02]

Liquid chromatography/tandem mass spectrometry determination of (4S,2RS)-2,5,5-trimethylthiazolidine-4-carboxylic acid, a stable adduct formed between D-(-)-penicillamine and acetaldehyde (main biological metabolite of ethanol), in plasma, liver and brain rat tissues. [2007]

Systematic review and meta-analysis: D-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis--Cochrane Hepato-Biliary Group. [2006.12]

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. [2006.10]

Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation in the corpus cavernosum in the rabbit. [2006.08]

Voluntary ethanol consumption decreases after the inactivation of central acetaldehyde by d-penicillamine. [2006.07.15]

Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. [2006.06.05]

Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation and superoxide formation in the aorta of the rabbit. [2006.02.15]

A pilot trial testing the feasibility of administering D-penicillamine to extremely low birth weight neonates. [2006.02]

[Penicillamine-induced bronchiolitis obliterans diagnosed by transbronchial lung biopsy] [2006.02]

D-penicillamine for primary sclerosing cholangitis. [2006.01.25]

Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. [2006]

Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. [2005.08]

Elastosis perforans serpiginosa secondary to D-penicillamine therapy with coexisting cutis laxa. [2005.07]

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. [2005.07]

D-Penicillamine improved laparoscopic and histological findings of the liver in a patient with Wilson's disease: 3-year follow-up after diagnosis of Coombs-negative hemolytic anemia of Wilson's disease. [2005.06]

Penicillamine induced pseudoxanthoma elasticum with elastosis perforans serpiginosa. [2005.05]

Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. [2005.02]

Improvement in liver pathology after 4 months of D-penicillamine in 5 doberman pinschers with subclinical hepatitis. [2005.01]

Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus. [2005.01]

Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine. [2005]

Synthesis and evaluation of long-acting D-penicillamine derivatives. [2005]

D-penicillamine for primary biliary cirrhosis. [2004.10.18]

Infant with severe penicillamine embryopathy born to a woman with Wilson disease. [2004.07.30]

D-penicillamine-induced pemphigus successfully treated with combination therapy of mizoribine and prednisolone. [2004.07]

Plasma D-penicillamine redox state evaluation by capillary electrophoresis with laser-induced fluorescence. [2004.04.25]

Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated. [2004.01]

[Minimal changes nephrotic syndrome associated to penicillamine treatment] [2004]

Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy. [2003.12]

The nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP) increases free radical generation and degrades left ventricular function after myocardial ischemia-reperfusion. [2003.12]

Epidermolysis bullosa acquisita-like reaction associated with penicillamine therapy for sclerodermatous graft-versus-host disease. [2003.12]

A case of penicillamine-induced dermopathy. [2003.09]

Goodpasture-like syndrome induced by D-penicillamine in a patient with systemic sclerosis: report and review of the literature. [2003.07]

Neurologic deterioration in a child with Wilson's disease on penicillamine therapy. [2003.05]

Effect of hypoxia on vasodilator responses to S-nitroso-N-acetylpenicillamine and levcromakalim in guinea pig basilar artery. [2003.05]

[Treatment of Wilson's disease with penicillamine and zinc salts: a follow-up study] [2003.02]

D-penicillamine and plasmapheresis in acute liver failure secondary to Wilson's disease. [2003.01]

Treatment of chronic haemophilic synovitis in humans with D-penicillamine. [2003.01]

Treatment of primary Sjogren's syndrome with D-penicillamine: a pilot study. [2002.11]

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. [2002.11]

Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine. [2002.08.30]

[Appropriate administration schedule of D-penicillamine for pediatric Wilson's disease patients based on urinary copper excretion] [2002.08]

D-penicillamine treatment for lipoid proteinosis. [2002.07]

Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia. [2002.05]

Clinical and histological spectrum of elastotic changes induced by penicillamine. [2002.05]

Breast enlargement induced by D-penicillamine. [2002.03]

d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. [2002.01]

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008